CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We raise our target price to $175 from $167, based on 16.0x our 2027 EPS estimate, a discount to NBIX's five-year historical forward P/E average of 21.1x. We raise our 2026 EPS view to $8.94 from $8.86 and our 2027 EPS estimate to $10.92 from $9.42. We continue to be bullish on shares of NBIX after the company announced a robust Q1 2026, with net product sales surpassing $800 million for the first time in the company's history, a 44% increase Y/Y. This performance was largely due to the continued growth of Ingrezza and the successful launch of Crenessity. We are also encouraged by the proposed $2.9 billion acquisition of Soleno Therapeutics, expected to close during Q2 2026, which will add Vykat XR to NBIX's commercial portfolio and strengthen the growth outlook. In our view, the company is advancing a deep pipeline successfully, with six new Phase I and four new Phase II programs that it plans to initiate during the year.